Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Regeneron Pharmaceuticals Inc. for $15.99, or

  • get full access to the entire website for at least 3 months from $49.99.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock

This is a one-time payment. There is no automatic renewal.

Regeneron Pharmaceuticals Inc. pages available today for free:

Cash Flow Statement
Quarterly Data

Beginner level

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company’s balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Regeneron Pharmaceuticals Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

Microsoft Excel LibreOffice Calc
3 months ended: Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Net income
Depreciation and amortization
Non-cash compensation expense
Other non-cash items, net
Deferred taxes
(Increase) decrease in Sanofi, trade, and other accounts receivable
(Increase) decrease in inventories
(Increase) decrease in prepaid expenses and other assets
Increase (decrease) in deferred revenue
Increase (decrease) in accounts payable, accrued expenses, and other liabilities
Changes in assets and liabilities
Adjustments to reconcile net income to net cash provided by (used in) operating activities
Net cash provided by (used in) operating activities
Purchases of marketable and other securities
Sales or maturities of marketable securities
Capital expenditures
Other
Net cash (used in) provided by investing activities
Proceeds from bridge loan facility
Proceeds in connection with finance lease liabilities
Payments in connection with finance lease liabilities
Proceeds (payments) in connection with finance lease liabilities (legacy)
Repayments of convertible senior notes
Payments in connection with reduction of outstanding warrants
Proceeds from issuance of Common Stock
Payments in connection with Common Stock tendered for employee tax obligations
Repurchases of Common Stock
Excess tax benefit from stock-based compensation
Net cash provided by (used in) financing activities
Net increase (decrease) in cash, cash equivalents, and restricted cash

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

Cash flow statement item Description The company
Net cash provided by (used in) operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Regeneron Pharmaceuticals Inc.’s net cash provided by (used in) operating activities decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Regeneron Pharmaceuticals Inc.’s net cash (used in) provided by investing activities decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Regeneron Pharmaceuticals Inc.’s net cash provided by (used in) financing activities increased from Q4 2019 to Q1 2020 but then decreased significantly from Q1 2020 to Q2 2020.